Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence

Addictive Behaviors

Volumn 34, Issue 6-7, 2009, Pages 581-586

  Kampman, Kyle M ^a   Pettinati, Helen M ^a   Lynch, Kevin G ^a   Xie, Hu ^a   Dackis, Charles ^a   Oslin, David W ^a,b   Sparkman, Thorne ^a   Sharkoski, Tiffany ^a   O'Brien, Charles P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Education and Clinical Center   (United States)

Author keywords

Acamprosate; Alcoholism; Clinical trial; Detoxification; Placebo

Indexed keywords

ACAMPROSATE; OXAZEPAM; PLACEBO; THIAMINE; VITAMIN;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MALE; OUTCOME ASSESSMENT; PAIN; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; RASH; REHABILITATION CARE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZEPAM; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SUBSTANCE WITHDRAWAL SYNDROME; TAURINE; TEMPERANCE; TREATMENT OUTCOME;

EID: 67349201396     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2009.03.014     Document Type: Article

References (34)

1. al Qatari M., Bouchenafa O., and Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcoholism: Clinical & Experimental Research 22 4 (1998) 810-814
2. Aubin H., Lehert P., Beaupere B., Jacquemin F., and Barrucand D. Tolerance de l'acamprosate aux medicaments du sevrage d'alcool. Essai multicentrique sur 591 alcooliques en sevrage. Alcoologie 16 (1994) 32-41
3. Baekeland F., Lundwall L., and Shanahan T. Correlates of subject attrition in the outpatient treatment of alcoholism. Journal of Nervous and Mental Diseases 157 (1973) 99-107
4. Boeijinga P.H., Parot P., Soufflet L., Landron F., Danel T., Gendre I., et al. Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology 50 1 (2004) 71-77
5. Cockroft D., and Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
6. Dahchour A., and De Witte P. Ethanol and amino acids in the central nervous system: Assessment of the pharmacological actions of acamprosate. Progress in Neurobiology 60 4 (2000) 343-362
7. Dahchour A., and De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcoholism: Clinical & Experimental Research 27 3 (2003) 465-470
8. Dahchour A., De Witte P., Bolo N., Nedelec J.F., Muzet M., Durbin P., et al. Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Research 82 2 (1998) 107-114
9. Diggle P., and Kenward M. Informative dropout in longitudinal data analysis (with Discussion). Applied Statistics 43 (1994) 43-93
10. Flannery B.A., Volpicelli J.R., and Pettinati H.M. Psychometric properties of the Penn Alcohol Craving Scale. [see comment]. Alcoholism: Clinical & Experimental Research 23 8 (1999) 1289-1295
11. Forest Pharmaceuticals. Campral package insert (2008)
12. Gual A., and Lehert P. Acamprosate during and after acute alcohol withdrawal: A double-blind placebo-controlled study in Spain. Alcohol & Alcoholism 36 5 (2001) 413-418
13. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 32 1 (1959) 50-55
14. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social & Clinical Psychology 6 4 (1967) 278-296
15. Harris B.R., Gibson D.A., Prendergast M.A., Blanchard J.A., Holley R.C., Hart S.R., et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcoholism: Clinical & Experimental Research 27 11 (2003) 1724-1735
16. Harris B.R., Prendergast M.A., Gibson D.A., Rogers D.T., Blanchard J.A., Holley R.C., et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcoholism: Clinical & Experimental Research 26 12 (2002) 1779-1793
17. Kranzler H., and Gage G. Acamprosate efficacy in alcohol-dependent patients: Summary of results from three pivital trials. American Journal of Addictions 717 (2008) 70-76
18. Kumari M., and Ticku M.K. Regulation of NMDA receptors by ethanol. Progress in Drug Research 54 (2000) 152-189
19. Lipha Pharmaceuticals. FDA Psychopharmacologic Advisory Committee briefing document for acamprosate 333 mg tablets (2002)
20. Littleton J. Acamprosate in alcohol dependence: Implications of a unique mechanism of action. Journal of Addiction Medicine 1 3 (2007) 115-124
21. Mason B.J., Goodman A.M., Dixon R.M., Hameed M.H., Hulot T., Wesnes K., et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27 4 (2002) 596-606
22. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 9 3 (1992) 199-213
23. Pettinati H., Weiss R., Miller W., Donovan D., Ernst D., and Rounsaville B. Medical management treatment manual: A clinical research guide for medically trained clinicians providing pharmacotherapy as part of the treatment for alcohol dependence (2004)
24. Pettinati H.M., Volpicelli J.R., Pierce Jr. J.D., and O'Brien C.P. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases 19 1 (2000) 71-83
25. Pettinati H.M., Weiss R.D., Dundon W., Miller W.R., Donovan D., Ernst D.B., et al. A structured approach to medical management: A psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. Journal of Studies on Alcohol Supplement(15) (2005) 170-178 discussion 168-179
26. Skinner H.A., and Horn J.L. Alcohol dependence syndrome: Measurement and validation. Journal of Abnormal Psychology 91 (1982) 199-209
27. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 Suppl 20 (1998) 22-33 quiz 34-57
28. Sobell L., and Sobell M. Timeline follow-back: A technique for assessing self-reported alcohol consumption in measuring alcohol consumption (1992), Humana Press
29. Staner L., Boeijinga P., Danel T., Gendre I., Muzet M., Landron F., et al. Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. Alcoholism: Clinical & Experimental Research 30 9 (2006) 1492-1499
30. Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., and Sellers E.M. Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). British Journal of Addiction 84 11 (1989) 1353-1357
31. Trevisan L., Fitzgerald L.W., Brose N., Gasic G.P., Heinemann S.F., Duman R.S., et al. Chronic ingestion of ethanol up-regulates NMDAR1 receptor subunit immunoreactivity in rat hippocampus. Journal of Neurochemistry 62 4 (1994) 1635-1638
32. Tsai G., Gastfriend D.R., and Coyle J.T. The glutamatergic basis of human alcoholism. [see comment]. American Journal of Psychiatry 152 3 (1995) 332-340
33. Tsai G.E., Ragan P., Chang R., Chen S., Linnoila V.M., and Coyle J.T. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. American Journal of Psychiatry 155 6 (1998) 726-732
34. Verheul R., Lehert P., Geerlings P.J., Koeter M.W.J., and van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology 178 2-3 (2005) 167-173